drugset / Trial / NCT05186922
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of CM326 in moderate-severe AD subjects.
Timeline
- Start
- 2022-02-17
- Primary completion
- 2023-01
- Completion
- 2023-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OCANKITUG | Monoclonal antibody | 55 mg | Subcutaneous |
| Subject | OCANKITUG | Monoclonal antibody | 110 mg | Subcutaneous |
| Subject | OCANKITUG | Monoclonal antibody | 220 mg | Subcutaneous |